Total Payments
$35,878
2024 Payments
$34,400
Companies
30
Transactions
102
Medicare Patients
7,122
Medicare Billing
$2.6M
Payment Breakdown by Category
Other$31,200 (87.0%)
Travel$2,579 (7.2%)
Food & Beverage$2,059 (5.7%)
Consulting$40.13 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,200 | 4 | 87.0% |
| Travel and Lodging | $2,579 | 11 | 7.2% |
| Food and Beverage | $2,059 | 85 | 5.7% |
| Consulting Fee | $40.13 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AIMMUNE THERAPEUTICS, INC. | $34,148 | 19 | $0 (2024) |
| Sanofi Pasteur Inc. | $410.32 | 7 | $0 (2018) |
| Allergan Inc. | $130.90 | 10 | $0 (2019) |
| Melinta Therapeutics, LLC | $124.47 | 9 | $0 (2023) |
| ABBVIE INC. | $121.29 | 7 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $114.11 | 5 | $0 (2024) |
| Merck Sharp & Dohme LLC | $112.27 | 8 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $98.97 | 2 | $0 (2019) |
| Gilead Sciences, Inc. | $78.63 | 5 | $0 (2024) |
| ADMA BioManufacturing LLC | $60.05 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34,400 | 32 | AIMMUNE THERAPEUTICS, INC. ($34,148) |
| 2023 | $242.59 | 13 | Melinta Therapeutics, LLC ($31.30) |
| 2022 | $93.60 | 5 | Takeda Pharmaceuticals U.S.A., Inc. ($60.83) |
| 2021 | $102.94 | 6 | AbbVie Inc. ($65.24) |
| 2020 | $13.48 | 1 | ViiV Healthcare Company ($13.48) |
| 2019 | $243.13 | 13 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($59.05) |
| 2018 | $375.67 | 17 | Sanofi Pasteur Inc. ($149.65) |
| 2017 | $405.89 | 15 | SANOFI PASTEUR INC. ($260.67) |
All Payment Transactions
102 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | HOSPIRA, INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA, CUTAQUIG | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: ANTIBIOTIC | ||||||
| 11/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $28.47 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,800.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 10/29/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Travel and Lodging | Cash or cash equivalent | $116.69 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 10/29/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Travel and Lodging | Cash or cash equivalent | $20.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 10/29/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Travel and Lodging | Cash or cash equivalent | $6.70 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 09/25/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Travel and Lodging | In-kind items and services | $445.96 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 09/25/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $124.98 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 08/19/2024 | Amgen Inc. | ACTIMMUNE (Biological) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Bone/Inflammation/Rare Disease | ||||||
| 08/19/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/31/2024 | ADMA BioManufacturing LLC | — | Consulting Fee | Cash or cash equivalent | $18.66 | General |
| 07/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $24.81 | General |
| Category: IMMUNOLOGY | ||||||
| 07/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.67 | General |
| 07/10/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: VIROLOGY | ||||||
| 07/03/2024 | CorMedix Inc. | DefenCath (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: Catheter Lock Solution | ||||||
| 06/06/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: ANTIBIOTIC | ||||||
| 05/21/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Travel and Lodging | Cash or cash equivalent | $423.37 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 05/14/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,800.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 04/23/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Travel and Lodging | In-kind items and services | $219.66 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 04/23/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $98.31 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 04/09/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,800.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 04/09/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,800.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 04/09/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Travel and Lodging | Cash or cash equivalent | $252.12 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 04/09/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Travel and Lodging | Cash or cash equivalent | $27.41 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,719 | 157,543 | $2.0M | $812,982 |
| 2022 | 20 | 1,699 | 215,664 | $1.9M | $715,568 |
| 2021 | 15 | 1,753 | 234,257 | $1.4M | $554,748 |
| 2020 | 18 | 1,951 | 146,156 | $1.4M | $541,966 |
Total Patients
7,122
Total Services
753,620
Medicare Billing
$2.6M
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1556 | Injection, immune globulin (bivigam), 500 mg | Office | 2023 | 38 | 6,160 | $893,200 | $347,374 | 38.9% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2023 | 11 | 11,400 | $285,000 | $133,751 | 46.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 291 | 1,074 | $187,950 | $96,999 | 51.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 382 | 1,382 | $165,840 | $83,092 | 50.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 164 | 670 | $93,800 | $31,389 | 33.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 208 | 225 | $72,488 | $29,615 | 40.9% |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 11 | 630 | $47,250 | $23,505 | 49.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 169 | 177 | $39,080 | $17,364 | 44.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 71 | 104 | $23,504 | $14,066 | 59.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 132 | $21,780 | $12,471 | 57.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 40 | 40 | $12,600 | $6,404 | 50.8% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 55 | 501 | $40,080 | $5,417 | 13.5% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 43 | 133,796 | $85,629 | $5,130 | 6.0% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 56 | 177 | $8,850 | $2,696 | 30.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 23 | 111 | $9,435 | $2,384 | 25.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 31 | 83 | $4,980 | $950.11 | 19.1% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 26 | 832 | $15,808 | $333.46 | 2.1% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 18 | 49 | $735.00 | $40.69 | 5.5% |
| J1556 | Injection, immune globulin (bivigam), 500 mg | Office | 2022 | 35 | 6,550 | $949,750 | $363,497 | 38.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 265 | 1,146 | $200,550 | $88,502 | 44.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 373 | 1,487 | $178,440 | $79,634 | 44.6% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2022 | 11 | 3,700 | $92,500 | $43,564 | 47.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 172 | 783 | $109,620 | $38,792 | 35.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 226 | 255 | $82,148 | $37,876 | 46.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 119 | 196 | $32,340 | $17,636 | 54.5% |
About Dr. Thomas Moore, MD
Dr. Thomas Moore, MD is a Infectious Disease healthcare provider based in Wichita, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1407851181.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Moore, MD has received a total of $35,878 in payments from pharmaceutical and medical device companies, with $34,400 received in 2024. These payments were reported across 102 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($31,200).
As a Medicare-enrolled provider, Moore has provided services to 7,122 Medicare beneficiaries, totaling 753,620 services with total Medicare billing of $2.6M. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Wichita, KS
- Active Since 06/17/2005
- Last Updated 08/03/2021
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1407851181
Products in Payments
- ZENPEP (Drug) $34,170
- NO PRODUCT DISCUSSED (Drug) $410.32
- AVYCAZ (Drug) $168.57
- LifeVest (Device) $98.97
- CUVITRU (Biological) $71.66
- DIFICID (Drug) $69.96
- HYQVIA (Biological) $53.28
- Baxdela (Drug) $42.98
- Arikayce (Drug) $37.98
- NUZYRA (Drug) $35.45
- Gamunex-C (Biological) $34.00
- Xerava (Drug) $33.13
- DOVATO (Drug) $32.66
- Kimyrsa (Drug) $31.08
- PANZYGA (Biological) $30.89
- ZERBAXA (Drug) $30.71
- VABOMERE (Drug) $29.45
- REBYOTA (Biological) $27.62
- DALVANCE (Drug) $27.57
- ARISTA AH FlexiTip (Device) $25.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Wichita
Dr. Maha Assi, Md, MD
Infectious Disease — Payments: $189,919
Infectious Disease $189,919
Dr. Margaret Hagan, Md, MD
Infectious Disease — Payments: $4,087
Infectious Disease $4,087
Dr. Keck Hartman, Md, MD
Infectious Disease — Payments: $2,429
Infectious Disease $2,429
Dr. Jerry Peterie, Md, MD
Infectious Disease — Payments: $2,180
Infectious Disease $2,180
Garret Seiler, D.o, D.O
Infectious Disease — Payments: $1,864
Infectious Disease $1,864
Dr. Shelley Jones, M.d, M.D
Infectious Disease — Payments: $1,718
Infectious Disease $1,718